Skip to main content

Cabozantinib für radiojodrefraktäre, differenzierte Schilddrüsenkarzinome

Cabozantinib for radioiodine-refractory differentiated thyroid cancer

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    Fugazzola L et al (2019) European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J 8:227–245

    Article  Google Scholar 

  2. 2.

    Haugen BR et al (2015) American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133

    Article  Google Scholar 

  3. 3.

    Brose MS et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940):319–328

    CAS  Article  Google Scholar 

  4. 4.

    Kiyota N et al (2017) Defining radioiodine-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by radioiodine-refractory criteria in the SELECT trial. Thyroid 27(9):1135–1141

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Costanza Chiapponi.

Ethics declarations

Interessenkonflikt

C. Chiapponi, M.J.M. Hartmann, D.A. Hescheler und H. Alakus geben an, dass kein Interessenkonflikt besteht.

Additional information

figureqr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chiapponi, C., Hartmann, M.J.M., Hescheler, D.A. et al. Cabozantinib für radiojodrefraktäre, differenzierte Schilddrüsenkarzinome. Onkologe 27, 1241–1242 (2021). https://doi.org/10.1007/s00761-021-01045-z

Download citation